ストックスクリーナーアプリを入手
1.7446
1.41%
-0.0254
前日終値:
$1.77
開ける：
$1.77
24時間の取引高:
59,741
Relative Volume:
0.10
時価総額：
$38.27M
収益：
$1.38M
当期純損益:
$-179.05M
株価収益率:
-0.2841
EPS:
-6.14
ネットキャッシュフロー:
$-155.03M
1週間 パフォーマンス:
-5.16%
1か月 パフォーマンス:
+5.12%
6か月 パフォーマンス:
+2.65%
1年 パフォーマンス:
+407.41%
1日の値動き範囲:
$1.75
$1.78
1週間の範囲:
$1.705
$1.87
52週間の値動き範囲:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
名前
Bioxcel Therapeutics Inc
セクター
電話
203-643-8060
住所
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.75 | 38.71M | 1.38M | -179.05M | -155.03M | -6.14 |
|
ZTS
Zoetis Inc
|
123.86 | 55.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.71 | 53.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.36 | 46.40B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.52 | 37.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
469.55 | 20.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-21 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-15 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-07-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-03-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-01 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-04-06 | 繰り返されました | BofA Securities | Buy |
| 2021-11-15 | ダウングレード | Goldman | Neutral → Sell |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-02-01 | 開始されました | UBS | Buy |
| 2020-10-30 | 開始されました | Goldman | Buy |
| 2020-09-02 | 開始されました | Jefferies | Buy |
| 2020-08-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-04 | 開始されました | Guggenheim | Buy |
| 2020-04-01 | 開始されました | BofA/Merrill | Buy |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
すべてを表示
Bioxcel Therapeutics Inc (BTAI) 最新ニュース
BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial - Law360
BioXcel Therapeutics submits sNDA for at-home use of IGALMI By Investing.com - Investing.com South Africa
BioXcel Therapeutics (BTAI) Advances Igalmi's Reach with FDA Sub - GuruFocus
BioXcel Therapeutics submits application to expand IGALMI use for at-home treatment - Investing.com Nigeria
BioXcel seeks FDA approval for at-home IGALMI use - TipRanks
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - The Manila Times
BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion - TradingView
BioXcel Therapeutics submits sNDA for at-home use of IGALMI - Investing.com
BioXcel Therapeutics Submits sNDA for IGALMI® At-Home Use - TradingView
What are the risks of holding BioXcel Therapeutics Inc.Weekly Trade Report & Capital Protection Trading Alerts - bollywoodhelpline.com
How BioXcel Therapeutics Inc. (BX20) stock moves on employment data2025 Fundamental Recap & Weekly Breakout Watchlists - bollywoodhelpline.com
Ag Plus, Inc. - Ag Plus, Inc.
Palmetto Grain Brokerage - Palmetto Grain Brokerage
1 Top Penny Stock to Watch Now - Yahoo Finance
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
BioXcel adds chief commercial officer as it prepares to expand agitation drug IGALMI’s reach - Hartford Business Journal
VIX Spike: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryTrade Entry Report & Smart Swing Trading Alerts - Bộ Nội Vụ
BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer - citybiz
Returns Recap: Is BioXcel Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
BioXcel Therapeutics names interim CCO amid IGALMI expansion - TipRanks
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics Announces Interim Chief Commercial Officer - TradingView
Drugmaker taps veteran to pursue at-home treatment for bipolar agitation - Stock Titan
Published on: 2026-01-09 03:25:25 - Улправда
Oklahoma City NewsThe Oklahoman - FinancialContent
Trend Review: How institutional buying supports BioXcel Therapeutics Inc. stockJuly 2025 Spike Watch & Breakout Confirmation Trade Signals - Улправда
Will BioXcel Therapeutics Inc. stock attract ESG investorsQuarterly Portfolio Summary & Consistent Profit Alerts - ulpravda.ru
Is BioXcel Therapeutics Inc. (BX20) stock undervalued historicallyJuly 2025 Breakouts & Fast Moving Stock Trade Plans - Улправда
What insider trading reveals about BioXcel Therapeutics Inc. stockTrade Risk Assessment & Fast Entry Momentum Alerts - ulpravda.ru
How robust is BioXcel Therapeutics Inc. (BX20) stock financial positionMACD Histogram Signals & Maximize Returns With Insights - ulpravda.ru
BioXcel Seeks FDA Nod For At-Home Use Of IGALMI In Bipolar And Schizophrenia Agitation - Nasdaq
BioXcel plans FDA submission for at-home agitation treatment - Investing.com
BioXcel plans FDA submission for at-home agitation treatment By Investing.com - Investing.com Nigeria
BTAI FinancialsIncome Statement - Quiver Quantitative
BioXcel Therapeutics, Inc. Plans Supplemental NDA Submission for IGALMI® Approval for At-Home Use in Treating Agitation Associated with Bipolar Disorders and Schizophrenia - Quiver Quantitative
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI - Chartmill
BioXcel Therapeutics enacts 1-for-16 reverse stock split - MSN
BioXcel Therapeutics (BTAI) price target decreased by 26.17% to 16.12 - MSN
Will BioXcel Therapeutics Inc. stock see insider buying2025 Sector Review & Real-Time Chart Breakout Alerts - Bộ Nội Vụ
Vipin Agarwal Net Worth (2025) - GuruFocus
Is BioXcel Therapeutics Stock Built to Withstand More Downside? - Trefis
What MACD trends signal for BioXcel Therapeutics Inc. (BX20) stockWeekly Market Report & Community Driven Trade Alerts - Улправда
EPS Watch: How robust is BioXcel Therapeutics Inc. (BX20) stock financial position2025 Earnings Surprises & AI Powered Market Entry Strategies - Улправда
Gap Down: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryWeekly Gains Report & Daily Momentum Trading Reports - Улправда
Can BioXcel Therapeutics Inc. stock maintain growth trajectoryEarnings Overview Summary & Verified Swing Trading Watchlist - Улправда
Risk Off: Will BioXcel Therapeutics Inc. stock see insider buying2025 Growth vs Value & AI Driven Stock Reports - Улправда
BioXcel Therapeutics (BTAI) Stock Analysis Report | Financials & Insights - Benzinga
Loss Report: Will BioXcel Therapeutics Inc. stock see insider buyingJuly 2025 Update & Daily Volume Surge Trade Alerts - Улправда
BioXcel Therapeutics Earnings Notes - Trefis
BioXcel Therapeutics holds annual stockholders meeting - MSN
BioXcel Therapeutics Holds Annual Stockholders Meeting - TipRanks
Bioxcel Therapeutics Inc (BTAI) 財務データ
収益
当期純利益
現金流量
EPS
2.55%
1.99%
大文字化:
|
ボリューム (24 時間):